EVER Neuro Pharma GmbH
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Subsidiary
- Established
- 1934-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.everpharma.com
Clinical Trials
14
Active:4
Completed:5
Trial Phases
4 Phases
Phase 1:1
Phase 2:3
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (44.4%)Phase 2
3 (33.3%)Phase 1
1 (11.1%)Phase 3
1 (11.1%)Cerebrolysin in CADASIL
Phase 2
Recruiting
- Conditions
- Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 30
- Registration Number
- 2024-513828-42-00
- Locations
- 🇨🇿
Fakultni Nemocnice V Motole, Prague, Czechia
IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE
Phase 2
Terminated
- Conditions
- Chronic StrokeSubacute Stroke
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 4
- Registration Number
- NCT04124367
- Locations
- 🇦🇹
Klinik Pirawarth, Bad Pirawarth, Austria
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 1851
- Registration Number
- NCT03480698
- Locations
- 🇦🇹
Landesklinikum Amstetten, Amstetten, Austria
🇦🇹Krankenhaus der Barmherzigen Brüder Eisenstadt, Eisenstadt, Austria
🇦🇹Universitätsklinik Innsbruck, Innsbruck, Austria
Cerebrolysin REGistry Study in Stroke
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 1823
- Registration Number
- NCT02541227
- Locations
- 🇦🇹
AKH Linz, Linz, Austria
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Registration Number
- NCT01822951
- Locations
- 🇦🇹
AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Austria
- Prev
- 1
- 2
- Next
News
No news found